NCT06824454PHASE2Recruiting

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Stanford University

Start Date

5/15/2025

Completion Date

5/1/2027

Summary

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Adult kidney transplant patients. * No known contraindications to Dipyridamole Exclusion Criteria: * Contraindications to Dipyridamole. * Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Interventions

DRUG

Dipyridamole 75 MG

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

HypophosphatemiaKidney Transplantation

Locations

Stanford University

Stanford, California 94304

United States